Comparative Pharmacology
Head-to-head clinical analysis: CIN QUIN versus PROCAINAMIDE HCL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CIN QUIN versus PROCAINAMIDE HCL.
CIN-QUIN vs PROCAINAMIDE HCL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cin-Quin (quinidine) is a class Ia antiarrhythmic agent that blocks sodium channels, prolonging the effective refractory period and slowing conduction velocity. It also has anticholinergic and alpha-adrenergic blocking properties.
Class Ia antiarrhythmic agent; blocks sodium channels, decreases phase 0 slope of action potential, prolongs refractory period, and increases action potential duration.
Quinine sulfate 648 mg (two 324 mg capsules) orally every 8 hours for 7 days, in combination with doxycycline, tetracycline, or clindamycin.
For life-threatening ventricular arrhythmias, IV: Loading dose: 100 mg administered at a rate of 25-50 mg/min, may repeat every 5 minutes until arrhythmia suppressed or up to a total of 500-1000 mg. Maintenance: IV infusion 1-4 mg/min. Oral: 250-500 mg every 3-6 hours; maximum 4 g/day.
None Documented
None Documented
Terminal elimination half-life is approximately 4-5 hours in healthy volunteers; prolonged to 8-12 hours in severe malaria or hepatic impairment.
Terminal elimination half-life: 2.5-4.7 hours (3 hours typical) in normal renal function; prolonged to 11-20 hours in renal impairment; NAPA half-life 6-8 hours (prolonged in renal failure).
Primarily hepatic metabolism; renal excretion of unchanged drug <20%. Biliary/fecal excretion accounts for ~30% of total clearance.
Primarily renal (50-60% unchanged via glomerular filtration and tubular secretion) with 10-30% as N-acetylprocainamide (NAPA) metabolite; minor biliary/fecal (<5%).
Category C
Category A/B
Antiarrhythmic (Class Ia)
Antiarrhythmic (Class Ia)